MedTrace Logo

A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients

NCT04189211 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-12-06

No results posted yet for this study

Summary

An Open-Label, Dose Escalation Phase I Clinical Trial on Safety, Tolerability and Pharmacokinetics of BAT8001 for Injection in Patients with HER2-Positive Solid Tumors (breast cancer or gastric cancer)。

Conditions

  • HER2-Positive Solid Tumors

Interventions

DRUG

BAT8001

IV infusions.

Sponsors & Collaborators

Principal Investigators

  • Shusen Wang, M.D. · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-07
Primary Completion
2019-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04189211 on ClinicalTrials.gov